The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

Cardiovascular Diseases Clinical Trial

— DESIFOR  

Official title:

The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03889314
• Other study ID #: DESIFOR
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: April 26, 2019
• Est. completion date: December 31, 2022

Study information

• Verified date: March 2022
• Source: Minneapolis Heart Institute Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will enroll patients who previously were not able to tolerate being on a statin medication due to muscle-related side effects. Research has shown that many people who have muscle symptoms on statin therapy do not experience the same side effects if they try it again later. This study is part of a larger effort to:

• See how common it is for patients to still be intolerant of statin medication after trying it a second time; and

• For those patients who do tolerate being on a statin after trying it a second time, see how common it is for them to still be taking the statin 3 months after completing the main part of the study.

Patients who agree to participate will be given a 5 month randomly allocated supply of statin and placebo and track their symptoms weekly.

Description:

This study is a single center, double-blinded randomized controlled trial for patients eligible for statin therapy by current guidelines, but not on statin therapy due to a history of statin intolerance. Patients will be provided a "DESIFOR" kit which includes 5 randomly allocated 4-week blister packs of capsules containing either 20mg of rosuvastatin or placebo. While blinded to treatment, patients will document the severity of musculoskeletal symptoms every week using a numerical scale. The primary endpoint will be the difference between the mean musculoskeletal symptom score while randomized to statin therapy compared to the mean score while on placebo. After completion of the study, the results will be unblinded and reviewed at a 6 month follow-up visit with the patient and, for patients with symptoms found to not correlate with statin therapy, a trial of non-blinded statin therapy over the next 3 months will be recommended. This study will serve as a pilot study to determine the feasibility and potential benefits of a larger multicenter trial with similar aims.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adults age 21-75 years old

• Statin eligible according to the 2013 ACC/AHA cholesterol guidelines, including individuals with:

• Known ASCVD

• Diabetes

• LDL-C > 190mg/dl

• 10-year ASCVD risk >7.5%

• Statin intolerant

• Defined by discontinuation of at least 2 separate statins due to potential musculoskeletal side effects

Exclusion Criteria:

• Women who are pregnant, nursing or attempting to become pregnant.

• Individuals deemed to be at very high CVD risk and therefore appropriate for a PCSK9 inhibitor including:

• Individuals with familial hypercholesterolemia with markedly elevated LDL-C levels

• Individuals with known ASCVD and recurrent events

• Individuals who are not otherwise clinically indicated to take 20mg rosuvastatin

• Individuals who experienced severe reactions in the past, including:

• Rhabdomyolysis

• Severe myositis

• Anaphylaxis

Related Conditions & MeSH terms

• Adverse Effect
• Cardiovascular Diseases
• Cardiovascular Risk Factor

Intervention

Drug:
• Rosuvastatin 20mg
Statin Therapy

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Minneapolis Heart Institute Foundation	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Minneapolis Heart Institute Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Musculoskeletal intolerance (as documented in study assessments)	Prevalence of musculoskeletal intolerance between the groups, defined by a lack of statistical difference in the mean musculoskeletal symptom score while on statin therapy compared to placebo, in patients previously identified as statin intolerant.	6 months
Secondary	Statin Utilization	Number of individuals taking statins 3 months post study	3 months